AVANT IMMUNOTHERAPEUTICS, INC.

Basic Information

AVANT IMMUNOTHERAPEUTICS, INC.
119 4TH AVE
NEEDHAM, MA, 02494 0272

Company Profile

n/a

Additional Details

Field Value
DUNS: n/a
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: n/a


  1. Immune modulation of radiation therapy with Flt3 ligand

    Amount: $1,081,749.00

    DESCRIPTION provided by applicant This proposal is a unique collaboration between a small but full capability biotechnology company and an academic institution specialized in radiation therapy ...

    SBIR Phase II 2015 Department of Health and Human Services National Institutes of Health
  2. Dendritic Cell-Targeted HIV Vaccine Product

    Amount: $1,988,027.00

    DESCRIPTION This proposal is a unique collaboration between a small but full capability biotechnology company and a premier academic institution and laboratory to develop a novel product for clinica ...

    SBIR Phase II 2014 Department of Health and Human Services National Institutes of Health
  3. Development and cGMP Manufacture of a Vitrified Typhoid Vaccine

    Amount: $750,000.00

    DESCRIPTION (provided by applicant): Typhoid fever is an infectious disease that annually afflicts an estimated 16 million people worldwide, resulting in 600,000 deaths. The etiologic agent of typhoid ...

    SBIR Phase II 2006 Department of Health and Human Services
  4. Live Attenuated Salmonella Vaccine Against Campylobacter

    Amount: $130,810.00

    DESCRIPTION (provided by applicant): The bacterium, Campylobacter jejuni, is a major cause of diarrheal illness in both the developed and developing world. It is estimated that Campylobacter may affe ...

    SBIR Phase I 2005 Department of Health and Human Services
  5. Feasibility Evaluation of an Oral Typhoid Fever Vaccine

    Amount: $126,861.00

    DESCRIPTION (provided by applicant): Ty800 is a live attenuated Salmonella typhi organism intended to be used as a prophylactic single dose oral vaccine for Typhoid fever. Ty800 may have advantages in ...

    SBIR Phase I 2003 Department of Health and Human Services
  6. LIVE ATTENUATED BACTERIAL VACCINES AGAINST ANTHRAX

    Amount: $120,511.00

    DESCRIPTION (provided by applicant): The ability to prepare anthrax spores inexpensively and deliver them in an aerosol form, and the high mortality rate of inhalation anthrax, has made Bacillus anthr ...

    SBIR Phase I 2002 Department of Health and Human Services
  7. N/A

    Amount: $218,442.00

    N/A

    SBIR Phase I 2000 Department of Health and Human Services
  8. N/A

    Amount: $103,263.00

    Not Available This proposed program is directed towards development and evaluation of a fiber optic sensor for detection of ammonia in the 100 ppb - 500 ppm range. The sensor technology is based on i ...

    SBIR Phase I 2000 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government